Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Key Points. Single-agent bortezomib produces durable hematologic responses and promising long-term overall survival in relapsed AL patients.Once-weekly bortezo

Saved in:

Bibliographic Details
Main Authors:	Reece, Donna E. (Author) , Hegenbart, Ute (Author) , Sanchorawala, Vaishali (Author) , Merlini, Giampaolo (Author) , Palladini, Giovanni (Author) , Bladé, Joan (Author) , Fermand, Jean-Paul (Author) , Hassoun, Hani (Author) , Heffner, Leonard (Author) , Kukreti, Vishal (Author) , Vescio, Robert A. (Author) , Pei, Lixia (Author) , Enny, Christopher (Author) , Esseltine, Dixie-Lee (Author) , van de Velde, Helgi (Author) , Cakana, Andrew (Author) , Comenzo, Raymond L. (Author)
Format:	Article (Journal)
Language:	English
Published:	September 8, 2014
In:	Blood Year: 2014, Volume: 124, Issue: 16, Pages: 2498-2506
ISSN:	1528-0020
DOI:	10.1182/blood-2014-04-568329
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2014-04-568329 Verlag, lizenzpflichtig, Volltext: https://ashpublications.org/blood/article/124/16/2498/33209/Long-term-follow-up-from-a-phase-1-2-study-of
Author Notes:	Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Vishal Kukreti, Robert A. Vescio, Lixia Pei, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, and Raymond L. Comenzo

Description
Summary:	Key Points. Single-agent bortezomib produces durable hematologic responses and promising long-term overall survival in relapsed AL patients.Once-weekly bortezo
Item Description:	Gesehen am 06.07.2020
Physical Description:	Online Resource
ISSN:	1528-0020
DOI:	10.1182/blood-2014-04-568329